Cirrhosis Clinical Trial
Official title:
A Prospective Validation of Child-Turcotte-Pugh-Kumar (CTPK) Score in Predicting Short Term Mortality in Patients With Liver Cirrhosis
The CTP score is one of the best proved severity score in predicting mortality in patients with cirrhosis. Portal hypertension and variceal bleed are significant causes of morbidity and mortality in patients with cirrhosis. The recently published CTPK score included variceal variceal bleed status to the CTP score which improved the accuracy of CTP score in predicting short term mortality. CTPK score needs prospective validation.
Once patients with cirrhosis experience decompensation, early mortality risk increases
sharply. Child-Pugh score has been the reference for many years for assessing the prognosis
of cirrhosis. The model for end-stage liver disease (MELD) score, which was originally
designed for assessing the prognosis of cirrhotic patients undergoing transjugular
intrahepatic portosystemic shunt (TIPS), is a continuous score relying on three objective
variables. Both CTP and MELD scores do not have portal hypertension as one of the
parameters. The investigators already know that portal hypertension is also an independent
prediction of mortality in patients of cirrhosis, however, both these scores fail to include
portal hypertension component in prediction of mortality.
A new severity score was devised by us by modifying existing CTP Score adding to it the
endoscopy parameter. The investigators modified the CTP score by adding the points for
variceal bleed status of the patients as follows: history of variceal bleed present - 3
points; no history of variceal bleed but large (grade III-IV) varices present - 2 points;
and no history of variceal bleed with small (grade I-II) or absent varices - 1 point. These
points were added to the conventional CTP score to obtain the CTPK score (maximum score 18,
minimum 6). CTPK score is a simple clinical tool and can be calculated at the bedside. It
includes the component of portal hypertension, which is not present in the CTP score.
In a retrospective study conducted by the Principal Investigator the CTPK score was found to
better predict the short term mortality (1 week, 2 week mortality regardless of treatment)
in patients of cirrhosis. It performs significantly better than the CTP score in predicting
early mortality, especially at 1 and 2 weeks in cirrhotics. Further prospective validation
of this score was warranted. Hence this study aims to prospectively validate the CTPK score
for predicting short term mortality in a cohort study of cirrhosis admitted in Sir Ganga Ram
Hospital.
STUDY OBJECTIVE
Comparison of CTP score, MELD score with new CTPK score in predicting the mortality at 1
week (primary objective), and at 2 weeks, 1 month, 2 months, 3 months and 6 months
(secondary objectives), regardless of the treatment offered.
Primary objective Prediction of short term mortality (1 week)
Secondary objective Prediction of long term mortality 2 weeks, 1 month, 2 months, 3 months
and 6 months
All patients of cirrhosis of liver who are admitted in department of gastroenterology &
hepatology (Unit - 1, either as inpatient or day care), Sir Ganga Ram Hospital for any
reason will be enrolled in study after taking consent & who fit in inclusion criterion. The
patients will be subjected to routine evaluation for etiology of cirrhosis and its
complications. Severity assessment of cirrhosis will be done by CTP score, MELD score and in
addition by new CTPK score. Patients will be treated as per discretion of treating
physician. Then patients will be followed up for 6 months at defined intervals. The follow
up will be taken as per following time intervals: 1 week, 2 week, 1 month, 2 months 3 months
and 6 months. The only parameter assessed in follow up will be their survival.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01884415 -
Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis
|
Phase 3 | |
Recruiting |
NCT05014594 -
Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT
|
Phase 2 | |
Not yet recruiting |
NCT03631147 -
The Effect of Rifaximin on Portal Vein Thrombosis
|
N/A | |
Completed |
NCT04939350 -
Evaluation of the Vaccination Coverage of Cirrhotic Patients Followed in the General Hospitals in France in 2021
|
||
Completed |
NCT02528760 -
To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis
|
N/A | |
Recruiting |
NCT05484206 -
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
|
Phase 1 | |
Not yet recruiting |
NCT05538546 -
Baveno VI Criteria in Dynamic Monitoring of High-risk Varices in Compensated Cirrhotic Patients
|
||
Not yet recruiting |
NCT04053231 -
Hepatocarcinoma Recurrence on the Liver Study - Part2
|
||
Recruiting |
NCT02983968 -
Use of the French Healthcare Insurance Database
|
||
Completed |
NCT02705534 -
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
|
Phase 3 | |
Completed |
NCT02596880 -
Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics
|
Phase 3 | |
Completed |
NCT02247414 -
Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection
|
Phase 4 | |
Withdrawn |
NCT01956864 -
Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer
|
Phase 1 | |
Completed |
NCT02016196 -
Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS
|
Phase 3 | |
Completed |
NCT02113631 -
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir
|
N/A | |
Completed |
NCT01447537 -
Mechanisms Involved in the Benefits of an Exercise Programme in Patients With Cirrhosis
|
N/A | |
Completed |
NCT01362855 -
Advance Care Planning Evaluation in Hospitalized Elderly Patients
|
||
Active, not recruiting |
NCT01205074 -
¹³C-Methacetin Breath Test (MBT) Methodology Study
|
Phase 2/Phase 3 | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT01231828 -
Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies.
|
N/A |